Abstract
This retrospective survey of the EBMT Leukaemia Working Party describes 78 patients with myelodysplasia (MDS) or secondary acute myelogenous leukaemia (sAML) who were given an allogeneic bone marrow transplant (BMT). The status of underlying disease at the time of transplantation was prognostic for the two-year disease-free survival which was 60% for patients transplanted in complete remission. Similar results were obtained for those with less advanced MDS (50-64%) who had not received any prior intensive chemotherapy. The results were significantly less favourable for those with more advanced disease who only partially responded to prior intensive chemotherapy (18%) while none of those who either relapsed or were resistent to chemotherapy survived. Allogeneic BMT can therefore be considered as curative treatment for patients with MDS. Patients with sAML who have a histocompatible donor should be given chemotherapy intensive enough to induce complete remission. If this is achieved these individuals have a prognosis comparable to those with de novo AML in first remission after BMT.
| Original language | English |
|---|---|
| Pages (from-to) | 38-39 |
| Number of pages | 2 |
| Journal | Bone Marrow Transplantation |
| Volume | 4 |
| Issue number | SUPPL. 3 |
| Publication status | Published - 1989 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes. / De Witte, T.; Zwaan, F.; Hermans, J.; Vernant, J.; Kolb, H.; Vossen, J.; Lonnqvist, B.; Beelen, D.; Ferrant, A.; Gmur, J.; Liu Yin, J.; Troussard, X.; Cahn, J.; Van Lint, M.; Gratwohl, A.
In: Bone Marrow Transplantation, Vol. 4, No. SUPPL. 3, 1989, p. 38-39.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes
AU - De Witte, T.
AU - Zwaan, F.
AU - Hermans, J.
AU - Vernant, J.
AU - Kolb, H.
AU - Vossen, J.
AU - Lonnqvist, B.
AU - Beelen, D.
AU - Ferrant, A.
AU - Gmur, J.
AU - Liu Yin, J.
AU - Troussard, X.
AU - Cahn, J.
AU - Van Lint, M.
AU - Gratwohl, A.
PY - 1989
Y1 - 1989
N2 - This retrospective survey of the EBMT Leukaemia Working Party describes 78 patients with myelodysplasia (MDS) or secondary acute myelogenous leukaemia (sAML) who were given an allogeneic bone marrow transplant (BMT). The status of underlying disease at the time of transplantation was prognostic for the two-year disease-free survival which was 60% for patients transplanted in complete remission. Similar results were obtained for those with less advanced MDS (50-64%) who had not received any prior intensive chemotherapy. The results were significantly less favourable for those with more advanced disease who only partially responded to prior intensive chemotherapy (18%) while none of those who either relapsed or were resistent to chemotherapy survived. Allogeneic BMT can therefore be considered as curative treatment for patients with MDS. Patients with sAML who have a histocompatible donor should be given chemotherapy intensive enough to induce complete remission. If this is achieved these individuals have a prognosis comparable to those with de novo AML in first remission after BMT.
AB - This retrospective survey of the EBMT Leukaemia Working Party describes 78 patients with myelodysplasia (MDS) or secondary acute myelogenous leukaemia (sAML) who were given an allogeneic bone marrow transplant (BMT). The status of underlying disease at the time of transplantation was prognostic for the two-year disease-free survival which was 60% for patients transplanted in complete remission. Similar results were obtained for those with less advanced MDS (50-64%) who had not received any prior intensive chemotherapy. The results were significantly less favourable for those with more advanced disease who only partially responded to prior intensive chemotherapy (18%) while none of those who either relapsed or were resistent to chemotherapy survived. Allogeneic BMT can therefore be considered as curative treatment for patients with MDS. Patients with sAML who have a histocompatible donor should be given chemotherapy intensive enough to induce complete remission. If this is achieved these individuals have a prognosis comparable to those with de novo AML in first remission after BMT.
UR - http://www.scopus.com/inward/record.url?scp=0024948270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024948270&partnerID=8YFLogxK
M3 - Article
C2 - 2697398
AN - SCOPUS:0024948270
VL - 4
SP - 38
EP - 39
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - SUPPL. 3
ER -